Nimbus Therapeutics CEO Jeb Keiper at #JPM24 (Brian Benton Photography)

Af­ter $4B Take­da deal, Nim­bus lays out ‘grand’ hopes for its next-gen im­munother­a­py drug

Just over a year ago, Nim­bus Ther­a­peu­tics closed one of the biggest sin­gle-drug deals in biotech, sell­ing its TYK2 in­hibitor to Take­da …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.